Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
BACKGROUND: Sorafenib is an orally available kinase inhibitor with activity at Raf, PDGFβ and VEGF receptors that is licensed for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Current evidence-based post-nephrectomy management of individuals with localized RCC consists of surveillance-based follow up. The SORCE trial is designed to investigate whether treatment with adjuvant sorafenib can reduce recurrence rates in this cohort. CASE PRESENTATION: Her...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 675.2KB)
- Publisher copy:
- Local pid:
- Deposit date:
- Copyright holder:
- Fairfax et al
- Copyright date:
- © 2012 Fairfax et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record